Key Insights

Highlights

Success Rate

85% trial completion

Published Results

37 trials with published results (23%)

Research Maturity

109 completed trials (68% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

11.8%

19 terminated out of 161 trials

Success Rate

85.2%

-1.4% vs benchmark

Late-Stage Pipeline

27%

44 trials in Phase 3/4

Results Transparency

34%

37 of 109 completed with results

Key Signals

37 with results85% success19 terminated

Data Visualizations

Phase Distribution

123Total
Not Applicable (29)
Early P 1 (2)
P 1 (15)
P 2 (33)
P 3 (29)
P 4 (15)

Trial Status

Completed109
Terminated19
Unknown13
Withdrawn7
Recruiting5
Active Not Recruiting4

Trial Success Rate

85.2%

Benchmark: 86.5%

Based on 109 completed trials

Clinical Trials (161)

Showing 20 of 20 trials
NCT05179876Phase 3RecruitingPrimary

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

NCT04175600Phase 3Active Not RecruitingPrimary

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT07473700Phase 2RecruitingPrimary

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

NCT06814145Phase 2Active Not RecruitingPrimary

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT02562235Phase 3Active Not RecruitingPrimary

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)

NCT07667829Not ApplicableNot Yet Recruiting

Vasopressor Agents in Pulmonary Hypertension Crisis

NCT07087613RecruitingPrimary

Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG

NCT03626688Phase 3Completed

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT01273259Phase 2Completed

Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults (DHEA-HTAP)

NCT00581087Phase 3Completed

Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults

NCT00595049Phase 4CompletedPrimary

Pulmonary Artery Remodelling With Bosentan

NCT03581695CompletedPrimary

Inflammatory Biomarkers of Pediatric Pulmonary Hypertension

NCT04945460Phase 2CompletedPrimary

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

NCT07079592Not ApplicableRecruiting

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

NCT03683186Phase 3Enrolling By Invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT02759419Phase 4CompletedPrimary

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

NCT05719415Not ApplicableRecruitingPrimary

Functional Pulmonary Capillary Surface Area in BPA for CTEPH

NCT04193046Early Phase 1CompletedPrimary

A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)

NCT01065454Phase 2CompletedPrimary

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

NCT00694850Phase 2CompletedPrimary

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Scroll to load more

Research Network

Activity Timeline